- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04396860
Тестирование использования иммунотерапевтических препаратов ипилимумаб и ниволумаб плюс лучевая терапия по сравнению с обычным лечением (темозоломид и лучевая терапия) для недавно диагностированной неметилированной глиобластомы MGMT
Рандомизированное открытое исследование фазы II/III ипилимумаба и ниволумаба по сравнению с темозоломидом у пациентов с недавно диагностированной MGMT (опухолевая O-6-метилгуанин ДНК-метилтрансфераза) неметилированной глиобластомой
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.
Обзор исследования
Статус
Подробное описание
PRIMARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs progression-free survival (PFS) versus adding temozolomide to radiotherapy in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation. (Phase II) II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs overall survival (OS) versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation. (Phase III)
SECONDARY OBJECTIVES:
I. To determine if adding ipilimumab and nivolumab to radiotherapy significantly prolongs PFS versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation for the phase III part of the study.
II. To determine if adding ipilimumab and nivolumab to radiotherapy significantly increases the 2-year OS rate versus adding temozolomide to radiotherapy in patients with newly diagnosed GBM without MGMT promoter methylation.
III. To evaluate the safety of adding ipilimumab and nivolumab to radiotherapy via comparative frequency between arms of specific adverse events of interest and frequency summaries for all adverse event types.
IV. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on patient reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM without MGMT promoter methylation.
V. To evaluate the effect of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on selected Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in patients with newly diagnosed GBM without MGMT promoter methylation.
VI. To evaluate the impact of adding ipilimumab and nivolumab to radiotherapy versus adding temozolomide to radiotherapy on neurocognitive function (NCF) in patients with newly diagnosed GBM without MGMT promoter methylation.
EXPLORATORY OBJECTIVES:
I. To explore biomarkers in pre-treatment archival tumor tissue that may predict efficacy of ipilimumab and nivolumab as measured by OS, PFS, and 2-year OS rate, such as but not limited to:
Ia. PDL1 expression; Ib. Mutational burden. II. To explore (in the two treatment separately) whether the MGMT protein expression correlates with clinical outcomes including OS, PFS, and 2-year OS rate.
III. To evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide orally (PO) daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain magnetic resonance imaging (MRI) throughout the trial.
ARM 2: Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab intravenously (IV) over 90 minutes once every 4 weeks (Q4W) for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial.
After completion of study treatment, patients are followed up every 3 months for year 1, then every 4 months for year 2, and then every 6 months thereafter.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Alabama
-
Birmingham, Alabama, Соединенные Штаты, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Соединенные Штаты, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Anaheim, California, Соединенные Штаты, 92806
- Kaiser Permanente-Anaheim
-
Auburn, California, Соединенные Штаты, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Соединенные Штаты, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Concord, California, Соединенные Штаты, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Соединенные Штаты, 92093
- UC San Diego Moores Cancer Center
-
Loma Linda, California, Соединенные Штаты, 92354
- Loma Linda University Medical Center
-
Los Angeles, California, Соединенные Штаты, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars Sinai Medical Center
-
Ontario, California, Соединенные Штаты, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Соединенные Штаты, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Roseville, California, Соединенные Штаты, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Соединенные Штаты, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Соединенные Штаты, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Соединенные Штаты, 95817
- University of California Davis Comprehensive Cancer Center
-
Torrance, California, Соединенные Штаты, 90509
- Torrance Memorial Medical Center
-
Torrance, California, Соединенные Штаты, 90505
- Torrance Memorial Physician Network - Cancer Care
-
Walnut Creek, California, Соединенные Штаты, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Colorado Springs, Colorado, Соединенные Штаты, 80907
- Penrose-Saint Francis Healthcare
-
Denver, Colorado, Соединенные Штаты, 80210
- AdventHealth Porter
-
Littleton, Colorado, Соединенные Штаты, 80122
- AdventHealth Littleton
-
Parker, Colorado, Соединенные Штаты, 80138
- AdventHealth Parker
-
-
Connecticut
-
Hartford, Connecticut, Соединенные Штаты, 06102
- Hartford Hospital
-
New Britain, Connecticut, Соединенные Штаты, 06050
- The Hospital of Central Connecticut
-
-
Delaware
-
Lewes, Delaware, Соединенные Штаты, 19958
- Beebe Medical Center
-
Millville, Delaware, Соединенные Штаты, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Соединенные Штаты, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Соединенные Штаты, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Соединенные Штаты, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Соединенные Штаты, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Соединенные Штаты, 19971
- Beebe Health Campus
-
-
Florida
-
Jacksonville, Florida, Соединенные Штаты, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Соединенные Штаты, 32803
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, Соединенные Штаты, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Соединенные Штаты, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Соединенные Штаты, 31404
- Memorial Health University Medical Center
-
Thomasville, Georgia, Соединенные Штаты, 31792
- Lewis Hall Singletary Oncology Center
-
-
Hawaii
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- Hawaii Cancer Care Inc-Liliha
-
Honolulu, Hawaii, Соединенные Штаты, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Соединенные Штаты, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- Island Urology
-
Kailua, Hawaii, Соединенные Штаты, 96734
- Castle Medical Center
-
Lihue, Hawaii, Соединенные Штаты, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- Queen's Cancer Center - Pearlridge
-
‘Aiea, Hawaii, Соединенные Штаты, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Idaho
-
Boise, Idaho, Соединенные Штаты, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Соединенные Штаты, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Fruitland, Idaho, Соединенные Штаты, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Соединенные Штаты, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Соединенные Штаты, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Соединенные Штаты, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Соединенные Штаты, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Соединенные Штаты, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Соединенные Штаты, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Соединенные Штаты, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University
-
Chicago, Illinois, Соединенные Штаты, 60612
- University of Illinois
-
Danville, Illinois, Соединенные Штаты, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Соединенные Штаты, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Соединенные Штаты, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Соединенные Штаты, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Соединенные Штаты, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Соединенные Штаты, 62401
- Carle Physician Group-Effingham
-
Elmhurst, Illinois, Соединенные Штаты, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, Соединенные Штаты, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Соединенные Штаты, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Соединенные Штаты, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Соединенные Штаты, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Соединенные Штаты, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Соединенные Штаты, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Соединенные Штаты, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Соединенные Штаты, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Соединенные Штаты, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Соединенные Штаты, 61938
- Carle Physician Group-Mattoon/Charleston
-
Naperville, Illinois, Соединенные Штаты, 60540
- Edward Hospital/Cancer Center
-
O'Fallon, Illinois, Соединенные Штаты, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Соединенные Штаты, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Соединенные Штаты, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Соединенные Штаты, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Соединенные Штаты, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Соединенные Штаты, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Соединенные Штаты, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Соединенные Штаты, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Соединенные Штаты, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Соединенные Штаты, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Соединенные Штаты, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Соединенные Штаты, 62702
- Springfield Clinic
-
Springfield, Illinois, Соединенные Штаты, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Соединенные Штаты, 61801
- Carle Cancer Center
-
Urbana, Illinois, Соединенные Штаты, 61801
- The Carle Foundation Hospital
-
Warrenville, Illinois, Соединенные Штаты, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Соединенные Штаты, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Ames, Iowa, Соединенные Штаты, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Соединенные Штаты, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Соединенные Штаты, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Соединенные Штаты, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Соединенные Штаты, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Соединенные Штаты, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Соединенные Штаты, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Соединенные Штаты, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Соединенные Штаты, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Соединенные Штаты, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Соединенные Штаты, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Соединенные Штаты, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Соединенные Штаты, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Соединенные Штаты, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70112
- Tulane University School of Medicine
-
New Orleans, Louisiana, Соединенные Штаты, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Соединенные Штаты, 04401
- Eastern Maine Medical Center
-
Bath, Maine, Соединенные Штаты, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Соединенные Штаты, 04915
- MaineHealth Waldo Hospital
-
Brewer, Maine, Соединенные Штаты, 04412
- Lafayette Family Cancer Center-EMMC
-
Portland, Maine, Соединенные Штаты, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Соединенные Штаты, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Соединенные Штаты, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Соединенные Штаты, 04074
- Maine Medical Partners Neurology
-
Scarborough, Maine, Соединенные Штаты, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Соединенные Штаты, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bel Air, Maryland, Соединенные Штаты, 21014
- UM Upper Chesapeake Medical Center
-
Columbia, Maryland, Соединенные Штаты, 21044
- Central Maryland Radiation Oncology in Howard County
-
Glen Burnie, Maryland, Соединенные Штаты, 21061
- UM Baltimore Washington Medical Center/Tate Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Соединенные Штаты, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Соединенные Штаты, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Соединенные Штаты, 48118
- Chelsea Hospital
-
Dearborn, Michigan, Соединенные Штаты, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Соединенные Штаты, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Соединенные Штаты, 48503
- Hurley Medical Center
-
Flint, Michigan, Соединенные Штаты, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Соединенные Штаты, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Соединенные Штаты, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Соединенные Штаты, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Соединенные Штаты, 49048
- Beacon Kalamazoo
-
Livonia, Michigan, Соединенные Штаты, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Соединенные Штаты, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, Соединенные Штаты, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Соединенные Штаты, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Соединенные Штаты, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Соединенные Штаты, 48764
- MyMichigan Medical Center Tawas
-
Troy, Michigan, Соединенные Штаты, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, Соединенные Штаты, 48093
- Henry Ford Health Warren Hospital
-
West Branch, Michigan, Соединенные Штаты, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Соединенные Штаты, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Соединенные Штаты, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Соединенные Штаты, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Соединенные Штаты, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Соединенные Штаты, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Соединенные Штаты, 55433
- Mercy Hospital
-
Edina, Minnesota, Соединенные Штаты, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Соединенные Штаты, 55432
- Unity Hospital
-
Maple Grove, Minnesota, Соединенные Штаты, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Соединенные Штаты, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Соединенные Штаты, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Соединенные Штаты, 55454
- Health Partners Inc
-
Saint Louis Park, Minnesota, Соединенные Штаты, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Соединенные Штаты, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Соединенные Штаты, 55102
- United Hospital
-
Stillwater, Minnesota, Соединенные Штаты, 55082
- Lakeview Hospital
-
-
Mississippi
-
Jackson, Mississippi, Соединенные Штаты, 39216
- University of Mississippi Medical Center
-
Southhaven, Mississippi, Соединенные Штаты, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Cape Girardeau, Missouri, Соединенные Штаты, 63703
- Saint Francis Medical Center
-
-
Montana
-
Billings, Montana, Соединенные Штаты, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Соединенные Штаты, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Соединенные Штаты, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Соединенные Штаты, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Соединенные Штаты, 59901
- Logan Health Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Соединенные Штаты, 68123
- Nebraska Medicine-Bellevue
-
Lincoln, Nebraska, Соединенные Штаты, 68516
- Cancer Partners of Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Соединенные Штаты, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Соединенные Штаты, 68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon, New Hampshire, Соединенные Штаты, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Соединенные Штаты, 07601
- Hackensack University Medical Center
-
Livingston, New Jersey, Соединенные Штаты, 07039
- Saint Barnabas Medical Center
-
Morristown, New Jersey, Соединенные Штаты, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Соединенные Штаты, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Соединенные Штаты, 08903
- Rutgers Cancer Institute of New Jersey
-
Pennington, New Jersey, Соединенные Штаты, 08534
- Capital Health Medical Center-Hopewell
-
Summit, New Jersey, Соединенные Штаты, 07902
- Overlook Hospital
-
-
New York
-
New York, New York, Соединенные Штаты, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Соединенные Штаты, 10065
- NYP/Weill Cornell Medical Center
-
New York, New York, Соединенные Штаты, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Соединенные Штаты, 14642
- University of Rochester
-
Syracuse, New York, Соединенные Штаты, 13210
- State University of New York Upstate Medical University
-
West Islip, New York, Соединенные Штаты, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Соединенные Штаты, 28210
- Atrium Health Pineville/LCI-Pineville
-
Concord, North Carolina, Соединенные Штаты, 28025
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Bismarck, North Dakota, Соединенные Штаты, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Соединенные Штаты, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Соединенные Штаты, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Соединенные Штаты, 44304
- Summa Health System - Akron Campus
-
Cleveland, Ohio, Соединенные Штаты, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Соединенные Штаты, 43214
- Riverside Methodist Hospital
-
Dublin, Ohio, Соединенные Штаты, 43016
- Dublin Methodist Hospital
-
-
Oklahoma
-
Lawton, Oklahoma, Соединенные Штаты, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Соединенные Штаты, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Clackamas, Oregon, Соединенные Штаты, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Соединенные Штаты, 97015
- Providence Cancer Institute Clackamas Clinic
-
Gresham, Oregon, Соединенные Штаты, 97030
- Legacy Mount Hood Medical Center
-
Newberg, Oregon, Соединенные Штаты, 97132
- Providence Newberg Medical Center
-
Portland, Oregon, Соединенные Штаты, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, Соединенные Штаты, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Соединенные Штаты, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, Соединенные Штаты, 97227
- Kaiser Permanente Northwest
-
Tualatin, Oregon, Соединенные Штаты, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Соединенные Штаты, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Broomall, Pennsylvania, Соединенные Штаты, 19008
- Crozer-Keystone Regional Cancer Center at Broomall
-
Chadds Ford, Pennsylvania, Соединенные Штаты, 19317
- Christiana Care Health System-Concord Health Center
-
Lancaster, Pennsylvania, Соединенные Штаты, 17601
- Lancaster General Ann B Barshinger Cancer Institute
-
Lancaster, Pennsylvania, Соединенные Штаты, 17602
- Lancaster General Hospital
-
Monroeville, Pennsylvania, Соединенные Штаты, 15146
- Forbes Hospital
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- UPMC-Shadyside Hospital
-
West Reading, Pennsylvania, Соединенные Штаты, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Соединенные Штаты, 15090
- Wexford Health and Wellness Pavilion
-
-
South Carolina
-
Rock Hill, South Carolina, Соединенные Штаты, 29730
- Rock Hill Radiation Therapy Center
-
-
South Dakota
-
Pierre, South Dakota, Соединенные Штаты, 57501
- Avera Cancer Institute at Pierre
-
Sioux Falls, South Dakota, Соединенные Штаты, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Соединенные Штаты, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Соединенные Штаты, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Collierville, Tennessee, Соединенные Штаты, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Memphis, Tennessee, Соединенные Штаты, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- Memorial Hermann Texas Medical Center
-
San Antonio, Texas, Соединенные Штаты, 78229
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
American Fork, Utah, Соединенные Штаты, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, Соединенные Штаты, 84720
- Sandra L Maxwell Cancer Center
-
Logan, Utah, Соединенные Штаты, 84321
- Logan Regional Hospital
-
Murray, Utah, Соединенные Штаты, 84107
- Intermountain Medical Center
-
Ogden, Utah, Соединенные Штаты, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Соединенные Штаты, 84604
- Utah Valley Regional Medical Center
-
Riverton, Utah, Соединенные Штаты, 84065
- Riverton Hospital
-
Salt Lake City, Utah, Соединенные Штаты, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84143
- LDS Hospital
-
St. George, Utah, Соединенные Штаты, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, Соединенные Штаты, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Соединенные Штаты, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Соединенные Штаты, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Inova Schar Cancer Institute
-
Richmond, Virginia, Соединенные Штаты, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Соединенные Штаты, 23970
- VCU Community Memorial Health Center
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, Соединенные Штаты, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Соединенные Штаты, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
-
West Virginia
-
Wheeling, West Virginia, Соединенные Штаты, 26003
- Wheeling Hospital/Schiffler Cancer Center
-
-
Wisconsin
-
Burlington, Wisconsin, Соединенные Штаты, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Germantown, Wisconsin, Соединенные Штаты, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Соединенные Штаты, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Соединенные Штаты, 54311
- Aurora BayCare Medical Center
-
Johnson Creek, Wisconsin, Соединенные Штаты, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
Kenosha, Wisconsin, Соединенные Штаты, 53142
- Aurora Cancer Care-Kenosha South
-
Madison, Wisconsin, Соединенные Штаты, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Соединенные Штаты, 54143
- Aurora Bay Area Medical Group-Marinette
-
Milwaukee, Wisconsin, Соединенные Штаты, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Соединенные Штаты, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Соединенные Штаты, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Соединенные Штаты, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Соединенные Штаты, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Соединенные Штаты, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Соединенные Штаты, 53406
- Aurora Cancer Care-Racine
-
Sheboygan, Wisconsin, Соединенные Штаты, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Summit, Wisconsin, Соединенные Штаты, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Соединенные Штаты, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wauwatosa, Wisconsin, Соединенные Штаты, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Соединенные Штаты, 53227
- Aurora West Allis Medical Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
-
PRIOR TO STEP 1 REGISTRATION:
-
No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin & eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the New York University (NYU) Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection (partial or complete) is required; a limited biopsy is not allowed because it will not provide sufficient tissue for MGMT analysis
- Note: The central pathology review and central MGMT results determine eligibility. Therefore, patients may be offered the opportunity to consent REGARDLESS of local pathology and MGMT results, and consent can occur BEFORE local pathology interpretation is finalized and BEFORE local MGMT testing is conducted
-
Contrast-enhanced brain MRI within 3 days after surgery
- MRI with Axial T2 weighted FLAIR {preferred} or T2 turbo spin echo (TSE)/fast spin echo (FSE) and 3-dimensional (3D) contrast-enhanced T1 sequences are required
- 3D pre contrast-enhanced T1 sequences are strongly suggested
-
Women of childbearing potential (WOCBP) and men who are sexually active with WOCBP must be willing to use an adequate method of contraception hormonal or barrier method of birth control; or abstinence during and after treatment
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry
-
PRIOR TO STEP 2 REGISTRATION:
-
Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
- Note: diagnoses of "Molecular glioblastoma" per the Consortium to Inform Molecular and Practical Approaches to Central Nervous System (CNS) Tumor Taxonomy (c-IMPACT-NOW) criteria or "CNS grade 4" per the World Health Organization (WHO) 2021 criteria are NOT relevant
-
MGMT promoter without methylation confirmed by central pathology review. Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or methylated MGMT promoter are excluded.
- Note: central pathology review and central MGMT results determine eligibility; local pathology or MGMT results cannot be used for eligibility/randomization
- Note: patients with methylated MGMT may be considered for enrollment on NRG-BN011
-
IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at step 2.)
- Note: this test is not being performed in real time as part of central review and will not be provided to sites from a centrally performed test
-
History/physical examination within 28 days prior to step 2 registration
-
Karnofsky Performance Status (KPS) >= 70 within 28 days prior to step 2 registration
-
Neurologic function assessment within 28 days prior to step 2 registration
-
Age >= 18 years
-
Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 10.0 g/dl is acceptable) (within 7 days prior to step 2 registration)
-
Leukocytes >= 2,000/mm^3 (within 7 days prior to step 2 registration)
-
Absolute neutrophil count >= 1,500/mm^3 (within 7 days prior to step 2 registration)
-
Platelets >= 100,000/mm^3 (within 7 days prior to step 2 registration)
-
Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN) (within 7 days prior to step 2 registration)
-
Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (within 7 days prior to step 2 registration)
-
Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula) (within 7 days prior to step 2 registration)
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
For women of childbearing potential (WOCBP), negative serum or urine pregnancy test within 7 days prior to step 2 registration. Note that it may need to be repeated if not also within 3 days prior to treatment start
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
Exclusion Criteria:
-
Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, gamma knife, cyber knife, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery;
- Note that 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
Current or planned treatment with any other investigational agents for the study cancer
-
Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
Pregnancy and nursing females due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or temozolomide
-
On any dose of any systemically administered (oral, rectal, intravenous) corticosteroid within 3 days prior to step 2 registration. Inhaled, topical, and ocular corticosteroids are allowed without limitation but must be recorded. Note that treatment with systemically administered corticosteroid after initiating study treatment is allowed as needed
-
Patients with known immune impairment who may be unable to respond to anti-CTLA 4 antibody
-
History of interstitial lung disease including but not limited to sarcoidosis or pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, defined as New York Heart Association functional classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, are excluded, as are patients on active immunosuppressive therapy. These include but are not limited to: patients with a history of immune-related neurologic disease, CNS or motor neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as autoimmune vasculitis [e.g., Wegener's Granulomatosis]), systemic lupus erythematosus (SLE), connective tissue diseases (e.g., systemic progressive sclerosis), scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome, Hashimoto's thyroiditis, autoimmune hepatitis are excluded because of the risk of recurrence or exacerbation of disease
-
Exceptions: patients with a history of the following conditions are not excluded, unless receiving active immunosuppressive therapy:
-
Vitiligo
-
Type I diabetes
-
Rheumatoid arthritis and other arthropathies
-
Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA)
- Anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
-
-
Patients who have evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation are also excluded
-
Current or planned therapy with warfarin
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: Arm I (radiation therapy, temozolomide)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks and simultaneously receive temozolomide PO daily for 6 weeks. After radiation, patients may wear the Optune device at the discretion of the patient and their treating physician. Beginning 1 month after radiation therapy, patients receive temozolomide on days 1-5. Treatment repeats every 28 days for up to 12 cycles at the discretion of the treating investigator in the absence of disease progression or unacceptable toxicity. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Другие имена:
Ancillary studies Given PO
Другие имена:
Undergo radiation therapy
Другие имена:
Undergo contrast-enhanced brain MRI
Другие имена:
Wear Optune device
Другие имена:
|
|
Экспериментальный: Arm II (radiation therapy, ipilimumab, nivolumab)
Patients undergo radiation therapy for 5 days per week (Monday-Friday) for a total of 30 fractions over 6 weeks. Starting on the first day of radiation, patients also receive ipilimumab IV over 90 minutes Q4W for 4 doses and nivolumab IV over 30 minutes every 2 weeks until disease progression. Patients also undergo contrast-enhanced brain MRI throughout the trial. |
Ancillary studies
Другие имена:
Given IV
Другие имена:
Ancillary studies Given IV
Другие имена:
Undergo radiation therapy
Другие имена:
Undergo contrast-enhanced brain MRI
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II)
Временное ограничение: From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up, whichever occurs first. Maximum follow-up time was 19.3 months.
|
|
Overall Survival (OS) (Phase III)
Временное ограничение: From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to date of death or last known follow-up. Maximum follow-up time was 19.3 months.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
PFS for the Entire Cohort (Phase II/III)
Временное ограничение: From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
Disease progression was confirmed by central review and defined using an adaptation of the Response Assessment in Neuro-Oncology criteria (Wen et al, J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15) with modification such that the first MRI performed following completion of radiotherapy is the baseline MRI for determination of radiographic disease. Progression-free survival time is defined as time from randomization to the date of first progression, death, or the last progression assessment with no documented progression (censored). Progression-free survival rates were estimated using the Kaplan-Meier method. |
From randomization to date of progression, death, or last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Overall Survival at 2 Years
Временное ограничение: From randomization to two years
|
Overall survival time is defined as time from randomization to the date of death from any cause or last known follow-up (censored). Two-year survival rates were to be estimated by the Kaplan-Meier method. |
From randomization to two years
|
|
Number of Participants by Highest Grade Adverse Event Reported
Временное ограничение: From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
Common Terminology Criteria for Adverse Events (version 5.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From randomization to date of last known follow-up. Maximum follow-up time was 19.3 months.
|
|
Change in MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) Symptom Severity at Six Months (Patient Reported Outcomes)
Временное ограничение: Baseline and six months
|
The MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) Symptom Severity subscale is a patient-reported outcome measure that assesses the severity of symptoms experienced by patients with brain tumors over the previous 24 hours. Possible subscale scores range from 0 to 10, with higher scores indicating a worse outcome. The change score was calculated as the 6-month value minus the baseline value. A negative change reflects improvement at 6 months and a positive change reflects decline at 6 months. |
Baseline and six months
|
|
Time to Neurocognitive Failure
Временное ограничение: From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
Neurocognitive failure is defined as the first instance of neurocognitive decline in any of six assessments, as determined by the reliable change index: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test (TMT) part A, TMT part B, and Controlled Oral Word Association (COWA). Failure time is defined as time from randomization to failure, disease progression or death (competing events), or last follow-up (censored). Neurocognitive failure rates and median failure times are estimated using the cumulative incidence method. Participants with no baseline or no follow-up neurocognitive function data were censored at day 1. |
From randomization to date of failure, disease progression, death, or last known follow-up whichever occurred first. Maximum follow-up time was 55.0 months.
|
|
Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 6 Months
Временное ограничение: Six months
|
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). The last response of each of the lists is the most severe response. |
Six months
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
ОС (если исследование прекращается на этапе II)
Временное ограничение: В конце II этапа обучения
|
В конце II этапа обучения
|
|
|
Tumor Biomarker Analyses
Временное ограничение: Up to 4 years
|
Will assess PD-L1 expression and mutational burden expression specifically. |
Up to 4 years
|
|
MGMT Protein Expression
Временное ограничение: Up to 4 years
|
Will assess the prognostic value of MGMT protein expression (in terms of predicting clinical outcomes such as PFS, OS, and 2-year OS rate) in the two treatment arms, separately. In addition, will evaluate if MGMT protein expression may be predictive of differential treatment effects between the two treatment arms. Correlation methods and survival modeling will be used to address these questions. |
Up to 4 years
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Andrew B Lassman, NRG Oncology
Публикации и полезные ссылки
Общие публикации
- Woroniecka K, Fecci PE. Immuno-synergy? Neoantigen vaccines and checkpoint blockade in glioblastoma. Neuro Oncol. 2020 Sep 29;22(9):1233-1234. doi: 10.1093/neuonc/noaa170. No abstract available.
- Lassman AB, Polley MC, Iwamoto FM, Sloan AE, Wang TJC, Aldape KD, Wefel JS, Gondi V, Gutierrez AN, Manasawala MH, Gilbert MR, Sulman EP, Wolchok JD, Green RM, Neil EC, Lukas RV, Goldlust SA, Snuderl M, Galbraith K, Dignam JJ, Won M, Mehta MP. Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial. J Clin Oncol. 2025 Sep 20;43(27):3032-3040. doi: 10.1200/JCO-25-00618. Epub 2025 Aug 8.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования
- Новообразования по гистологическому типу
- Новообразования железистые и эпителиальные
- Глиома
- Новообразования, нейроэпителиальные
- Нейроэктодермальные опухоли
- Новообразования, зародышевые клетки и эмбриональные
- Новообразования, нервная ткань
- Глиосаркома
- Аминокислоты, пептиды и белки
- Белки
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Следственные методы
- Терапия
- Азолы
- Фармакологические действия
- Химические действия и используют
- Биологические факторы
- Физические явления
- Дакарбазин
- Триазены
- Имидазолы
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Специальное использование химических веществ
- Химические методы, аналитические
- Анализ спектра
- Рецепторы, клеточная поверхность
- Мембранные белки
- Антигены
- Антигены, поверхность
- Биомаркеры
- Диагностическое использование химических веществ
- Рецепторы, иммунологические
- Антигены, дифференциация, Т-лимфоцит
- Антигены, дифференциация
- Белки иммунной контрольной точки
- Костимуляторные и ингибирующие Т-клеточные рецепторы
- Темозоломид
- Ниволумаб
- Ипилимумаб
- Лучевая терапия
- Излучение
- Магнитно -резонансная спектроскопия
- Контрастные СМИ
- CTLA-4 антиген
Другие идентификационные номера исследования
- NCI-2020-03404
- U10CA180868 (Грант/контракт NIH США)
- NCI-2020-03404 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- NRG-BN007 (Другой идентификатор: CTEP)
- NRG-BN007 (Другой идентификатор: NRG Oncology)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .